Clinical Application: Weight Management in Modern Healthcare

Understand the importance of clinical application of weight management in promoting healthier lifestyles and weight control.

Abstract

In this educational post, I present a clinically integrated approach to obesity care, drawing from my perspective as a Doctor of Chiropractic, an Advanced Practice Registered Nurse with board certification as a Family Nurse Practitioner, and a functional medicine clinician working in a multidisciplinary setting. Obesity is one of the most prevalent, misunderstood, and undertreated chronic diseases. In the United States, over 100 million people live with obesity, yet less than 1% receive appropriate pharmacological treatment. This post explores the full clinical landscape of obesity pharmacotherapy, from established sympathomimetics to cutting-edge dual GLP-1/GIP receptor agonists like tirzepatide. I will interpret key case scenarios, discuss the physiological underpinnings of why each therapy works, and explain how our team at Injury Medical Clinic PA in El Paso, Texas, integrates chiropractic care, functional medicine, and rehabilitation under the expert medical direction of Dr. Maria Guadalupe Cardenas, MD, to optimize patient outcomes. The goal is to equip clinicians and patients with the knowledge needed to close the enormous treatment gap in obesity care, treating the whole person, not just the number on the scale.

About the Authors: A Multidisciplinary Approach to Obesity Care in El Paso, Texas

I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. At Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, in El Paso, Texas, my team and I deliver multidisciplinary, integrative care for individuals with complex chronic conditions such as obesity, metabolic dysfunction, musculoskeletal pain, and personal injuries. Our clinical model is built around a collaborative framework that ensures every patient receives both evidence-based medical management and hands-on functional rehabilitation.

Serving as our Medical Director and Collaborative Physician is Dr. Maria Guadalupe Cardenas, MD (NPI #1164426749, Texas MD License #J2933). Board Certified in Internal Medicine, Dr. Cardenas brings over 40 years of experience as an internist, providing an extraordinary depth of knowledge to our practice. She provides essential medical direction, physician oversight, risk assessment, and pharmacological management for patients with complex metabolic and systemic conditions, including obesity and its many comorbidities.

This multidisciplinary setup, common in integrative and injury care clinics, allows our team to:

• Provide medical oversight and pharmacological management through Dr. Cardenas’s internal medicine expertise.
• Deliver chiropractic care and spinal rehabilitation through my hands-on clinical practice.
• Integrate functional medicine protocols, including nutritional assessment, gut health optimization, and hormone evaluation.
• Manage personal injury cases that often involve patients with pre-existing metabolic conditions like obesity.
• Offer rehabilitation services tailored to the biomechanical consequences of excess body weight.

Our shared philosophy is simple: that obesity is a systemic disease that demands a systemic solution. We believe in treating the whole person by using modern, evidence-based research to guide our decisions and integrating safe pharmacology with biomechanical correction, nervous system regulation, and behavior change. My clinical observations and educational content are available at WellnessDoctorRx.com and through my professional profile on LinkedIn.

Understanding Obesity as a Chronic, Relapsing Disease

One of the most critical clinical reframes of the past decade is recognizing obesity not as a lifestyle failure, but as a chronic, progressive, relapsing, and treatable disease. This is a position formally adopted by major medical organizations, including the American Medical Association and the Endocrine Society (Apovian et al., 2015).

The evidence for this is compelling. When patients stop taking anti-obesity medications, their weight reliably returns, just as hypertension rebounds when antihypertensives are stopped. This relapsing nature is not a sign of patient failure; it’s a sign of the disease’s powerful biological grip on metabolism and appetite regulation.

Key Characteristics of Obesity as a Chronic Disease

• Progressive: Without intervention, body weight and adiposity tend to increase over time.
• Relapsing: Weight regain is biologically driven by powerful hormonal and neurological adaptations.
• Multifactorial: It is caused by a complex interplay of genetic, hormonal, environmental, and behavioral factors.
• Treatable: Significant and sustained weight loss is achievable with appropriate medical, behavioral, and surgical interventions.

Adipose tissue dysfunction is central to this disease. As fat mass increases, adipocytes (fat cells) become hypertrophic and dysfunctional, releasing pro-inflammatory cytokines like TNF-alpha and IL-6. This creates a state of chronic low-grade systemic inflammation that drives insulin resistance, cardiovascular disease, and musculoskeletal deterioration (Hotamisligil, 2017).

Epidemiology and the Social Determinants of Obesity

According to the CDC, 41.9% of Americans meet the criteria for obesity (BMI ≥ 30), and 9.2% have severe obesity (BMI ≥ 40) (CDC, 2022). These staggering numbers are shaped heavily by what we call the social determinants of obesity. While it’s easy to reduce obesity to “eating too much and moving too little,” the reality is far more complex.

Social and Environmental Factors Contributing to Obesity

• Economic instability: High-calorie, nutrient-poor foods are often cheaper and more accessible.
• Built environment: A lack of safe parks or sidewalks limits opportunities for physical activity.
• Food deserts: Many communities have limited access to fresh, whole foods.
• Education: Lower health literacy often correlates with reduced nutritional awareness.
• Technology: Increased screen time and sedentary behavior are linked to rising obesity rates.

The body’s hormonal architecture also plays a huge role. Hormones like ghrelin (the hunger hormone), GLP-1 (which signals fullness), and leptin (the satiety hormone) are critical for appetite regulation. Research also shows that our gut microbiota can influence how we absorb calories and even our eating behaviors (Turnbaugh et al., 2006).

The Clinical Inertia Problem: Why Obesity Is Undertreated

Despite being the most prevalent chronic disease in the U.S., the treatment gap is staggering. Fewer than 1% of the 100 million Americans with obesity receive a prescription for anti-obesity medication (Eisenberg et al., 2022).

Barriers to Obesity Treatment

• Weight bias and stigma: The persistent belief that obesity is a result of laziness or a lack of willpower.
• Reimbursement gaps: Many anti-obesity medications are not covered by insurance.
• Time constraints: Comprehensive obesity counseling takes more time than most clinical visits allow.
• Lack of clinical training: Many providers receive minimal education in obesity medicine.

Weight bias is a particularly insidious barrier. Harvard’s Implicit Bias studies have found that weight bias is the only category of bias that has been increasing over time. This is a clinical issue, as studies show that weight bias independently increases morbidity and mortality, separate from the physiological effects of excess weight (Puhl & Heuer, 2010). The double standard is stark: we would find it unconscionable if only 1% of providers offered HIV treatment, yet that is the reality for obesity pharmacotherapy.

Appetite Regulation: The Neuroendocrine Physiology Driving Obesity

To treat obesity effectively, we must understand the complex neuroendocrine architecture of appetite. It’s not about willpower; a sophisticated network of signals governs it.

Key Hormonal Regulators of Appetite

• Leptin: Secreted by fat tissue to signal satiety. In obesity, leptin resistance develops, meaning the brain no longer responds to these signals, perpetuating hunger.
• Ghrelin: Produced in the stomach, it stimulates hunger. Its regulation is often dysregulated in individuals with obesity.
• GLP-1: Released from the gut in response to food, it slows gastric emptying and reduces appetite.
• Cortisol: Chronic stress elevates cortisol, which promotes central adiposity and cravings for calorie-dense foods.
• POMC (Pro-opiomelanocortin): A hypothalamic pathway that, when activated, promotes satiety.

Understanding these pathways explains why patients often can’t just “eat less and move more.” Their neurochemical environment is actively working against them. Pharmacotherapy helps correct these dysfunctional biological signals.

Binge-Eating Disorder: Recognition, Impact, and Why It Matters

In my practice, I find that unrecognized binge-eating disorder (BED) is often a major driver of weight gain and plateaus. It’s crucial to screen for it with a compassionate, structured response.

The clinical picture of BED involves recurrent episodes of eating significantly more food than most people would in a similar period, coupled with a sense of a lack of control. According to the DSM-5, these episodes are associated with three or more of the following: eating rapidly, eating until uncomfortably full, eating when not hungry, eating alone due to embarrassment, and feeling disgusted or guilty afterward.

Physiological Underpinnings

• Neurobiology: Dysregulation in dopamine and norepinephrine circuits can heighten reward-seeking behavior and impair impulse control, while serotonin imbalances may affect mood and satiety (Kessler et al., 2016).
• Hormonal Signals: Hormones like ghrelin, leptin, and insulin are often perturbed in both obesity and BED, creating a biochemical cycle that reinforces overeating.
• Stress Response: Chronic stress elevates cortisol, which interacts with the brain’s limbic system, amplifying craving-driven behaviors related to emotion regulation (Tomiyama, 2019).

Treating obesity without addressing co-occurring BED often leads to frustration and poor adherence. This is why our approach integrates targeted therapy with chiropractic and rehabilitation to create sustained momentum.

Pharmacological Treatment of Obesity: Mechanisms and Indications

Under Dr. Cardenas’s medical direction, we evaluate the risk-benefit profile of each medication, confirming indications and aligning treatment with comorbidities. A clinically meaningful target for patients is a 5-10% body weight reduction over six months, as even a 3-5% loss produces measurable health improvements (Jensen et al., 2014).

Treatment Thresholds by BMI

BMI	Recommended Intervention
≥ 25 with comorbidities	Lifestyle intervention (diet, activity, behavior)
≥ 30 regardless of comorbidities	Lifestyle intervention
≥ 27 with comorbidities	Pharmacotherapy
≥ 30 without comorbidities	Pharmacotherapy
≥ 35 with comorbidities	Bariatric surgery consideration
≥ 40 without comorbidities	Bariatric surgery consideration

Short-Term Anti-Obesity Medications: Sympathomimetic Agents

Phentermine is the most commonly prescribed short-term agent. It’s a sympathomimetic amine that stimulates catecholamine release in the hypothalamus to reduce appetite. While effective for short-term use, it’s contraindicated in patients with cardiovascular disease or uncontrolled hypertension and requires monthly monitoring of blood pressure and heart rate. Its limitations include tachyphylaxis (diminishing response over time) and a potential for dependence.

Long-Term Anti-Obesity Medications

Orlistat (Xenical/Alli)

• Mechanism: It inhibits gastrointestinal lipase enzymes, preventing the absorption of about 30% of dietary fat (Torgerson & Hauptman, 2004). This creates a behavioral feedback loop, as high-fat meals cause significant GI side effects, disincentivizing fat consumption.
• Why/When: It’s useful for patients who prefer a non-systemic medication. Patients must adhere to a low-fat diet and supplement with fat-soluble vitamins (A, D, E, K).

Phentermine/Topiramate (Qsymia)

• Mechanism: This combination therapy uses phentermine for appetite suppression and topiramate, which contributes through multiple mechanisms, including GABA receptor modulation.
• Why/When: Approved for long-term use in ages 12 and older, it requires gradual dose titration to minimize side effects like cognitive dulling. It is contraindicated in pregnancy due to being teratogenic.

Naltrexone/Bupropion (Contrave)

• Mechanism: This combination targets the POMC system. Bupropion activates POMC neurons to promote satiety, while naltrexone blocks a negative feedback loop, amplifying bupropion’s effect (Greenway et al., 2010).
• Why/When: It’s a strong option for patients who also have depressive symptoms, as it addresses both appetite and reward-based eating. It should be avoided in patients with seizure disorders or those on chronic opioid therapy.

GLP-1 and Dual GIP/GLP-1 Receptor Agonists: The New Standard of Care

The most significant advances in obesity pharmacotherapy involve GLP-1 receptor agonists and the newer dual incretin agents. These medications mimic gut hormones to produce robust and sustained weight loss.

Liraglutide (Saxenda)

• Mechanism: A daily injectable GLP-1 receptor agonist that slows gastric emptying, acts on the hypothalamus to reduce appetite, and stimulates insulin secretion.
• Clinical Significance: Clinical trials showed an average weight loss of approximately 5-8% over 56 weeks (Pi-Sunyer et al., 2015).

Semaglutide (Wegovy)

• Mechanism: A more potent, weekly injectable GLP-1 receptor agonist.
• Clinical Significance: The STEP trials demonstrated an unprecedented average weight loss of 14.9% from baseline over 68 weeks (Wilding et al., 2021).

Tirzepatide (Zepbound)

• Mechanism: This is the most advanced option, a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. Engaging two incretin pathways creates a synergistic effect, leading to superior weight loss.
• Clinical Significance: The SURMOUNT trials demonstrated an average weight loss of up to 22.5% from baseline, approaching the outcomes seen with bariatric surgery (Jastreboff et al., 2022).
• Why/When: These are first-line considerations for patients with type 2 diabetes or high cardiometabolic risk. We titrate the dose slowly to manage GI side effects and preserve adherence. All are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2.

Specialized Pharmacotherapy: Lisdexamfetamine (Vyvanse) for Binge Eating Disorder

Lisdexamfetamine dimesylate (Vyvanse) is the only FDA-approved pharmacotherapy for binge eating disorder (BED) (McElroy et al., 2016). In my practice, I routinely screen for BED, as it is a prevalent and underdiagnosed driver of excess caloric intake in the obese population. As a CNS stimulant, Vyvanse is thought to reduce binge frequency by improving impulse control through dopaminergic and noradrenergic modulation. When prescribing it, we titrate cautiously, monitor heart rate and blood pressure, and collaborate with mental health clinicians, especially if the patient also has anxiety.

Avoiding Obesogenic Medications: First, Do No Harm

Before starting anti-obesity therapy, it is my first principle to audit a patient’s entire medication list for obesogenic agents that may be contributing to weight gain.

Common Obesogenic Drug Classes to Review

• Antidepressants: Mirtazapine, TCAs, some SSRIs (paroxetine).
• Antipsychotics: Olanzapine, clozapine.
• Mood stabilizers/Anticonvulsants: Valproate, gabapentin.
• Antidiabetic agents: Sulfonylureas (like glyburide), insulin (in excess).
• Corticosteroids: Chronic glucocorticoid therapy.

Where clinically appropriate, switching to weight-neutral or weight-reducing alternatives can be a powerful first step. From my clinical observation, this single change can be a force multiplier; patients often report normalization of appetite within weeks, making other lifestyle changes feel more achievable.

---

Discovering the Benefits of Chiropractic Care- Video

---

Integrative Chiropractic and Functional Medicine in Obesity Management

At Injury Medical Clinic PA, my clinical philosophy is that pharmacotherapy alone is insufficient. The biomechanical, inflammatory, and functional dimensions of obesity require equally rigorous attention. This is where integrative chiropractic care becomes foundational.

How Chiropractic Care Supports Obesity Treatment

Obesity imposes immense mechanical stress on the musculoskeletal system, accelerating degenerative changes in the spine, hips, and knees. Patients with obesity frequently present with:

• Chronic low back pain from increased lumbar lordosis and disc compression.
• Knee osteoarthritis from elevated joint loading forces.
• Reduced mobility, which creates a vicious cycle of inactivity and further weight gain.

Chiropractic spinal manipulation and mobilization address these consequences by restoring joint mobility, reducing mechanical pain, and improving neuromuscular function. By reducing pain barriers, chiropractic care helps patients engage more fully in the exercise component of their weight management plan.

From my clinical practice:

• When patients experience less low back and knee pain, they immediately increase their daily steps and confidence. This directly correlates with greater weight-loss velocity when they are on medications such as GLP-1s.
• I’ve observed that restoring thoracic mobility and diaphragmatic function through adjustments and breathing drills often improves interoceptive awareness and reduces impulsive eating triggers.

Functional Medicine Integration

My functional medicine training informs an approach that investigates the root metabolic causes of weight dysregulation, such as gut microbiome imbalances, thyroid dysfunction, and chronic inflammation. This layer complements Dr. Cardenas’s internal medicine oversight, ensuring patients receive both pharmaceutical-grade medical care and systems-biology-informed metabolic optimization.

Pipeline and Emerging Therapies: What’s Coming and Why It Matters

The field is rapidly expanding. Triple agonists like retatrutide (GLP-1/GIP/glucagon) are showing even larger weight reductions in trials, with promising signals of less lean mass loss (Jastreboff et al., 2023). Oral versions of semaglutide are also on the horizon, which could expand access for injection-averse patients (O’Neil et al., 2023). This matters because preserving lean mass is essential for protecting metabolic rate and maintaining function. Combining these emerging medications with resistance training will be key.

Clinical Cases: How We Decide and Why

Case 1: 45-year-old male with hypertension, type 2 diabetes, and hyperlipidemia.

• Our Reasoning: First, do no harm. His glyburide prescription is obesogenic. We would work to deprescribe it.
• Protocol:

1. 1. Optimize metformin to improve insulin sensitivity.
   2. Initiate a GLP-1 RA or tirzepatide. For a patient with diabetes, semaglutide (Ozempic) or tirzepatide (Mounjaro) is an excellent choice, with strong evidence of cardiometabolic benefits (Frías et al., 2021).
   3. Integrate chiropractic care to address any low back or knee pain limiting his activity.

• Why This Works: We align pharmacology with his metabolic needs while using chiropractic care to remove physical barriers to exercise, creating a synergistic effect.

Case 2: 38-year-old male with BMI 34, prediabetes, and depression.

• Our Reasoning: This patient’s presentation suggests a link between mood, reward-seeking behavior, and metabolic health.
• Protocol:

1. 1. Consider naltrexone-bupropion for its dual benefit on appetite and mood.
   2. Use chiropractic and functional strategies to decrease sympathetic overdrive, such as improving thoracic mobility and teaching breathing drills to support vagal tone.

• Why This Works: This approach aligns pharmacology with the brain’s reward circuitry, while non-pharmacologic care reduces allostatic load and musculoskeletal pain, thereby enabling greater activity.

Conclusion: Closing the Treatment Gap Through Integrative, Evidence-Based Care

Obesity is a chronic, biologically complex disease that demands the same clinical seriousness and compassion we apply to any other major illness. The powerful pharmacological tools available today, from combination agents to dual incretin therapies, enable us to achieve life-changing, sustained weight loss.

At Injury Medical Clinic PA in El Paso, Texas, Dr. Maria Guadalupe Cardenas and I exemplify the integrative model of modern obesity care. Dr. Cardenas ensures medical safety and precise pharmacology, while I address musculoskeletal and autonomic obstacles that limit activity, recovery, and self-regulation.

Closing the obesity treatment gap is a clinical and moral imperative. With the tools, knowledge, and interdisciplinary frameworks now available, there is no acceptable reason to leave the majority of patients with obesity untreated.

References

• Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015). Pharmacological management of obesity: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 100(2), 342–362.
• Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Tsochatzis, E. A., & Rowe, I. A. (2016). Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomized, placebo-controlled phase 2 study. The Lancet Gastroenterology & Hepatology, 1(1), 35-43.
• Centers for Disease Control and Prevention. (2022). Adult obesity facts. National Center for Health Statistics.
• Eisenberg, D., Shikora, S. A., Aarts, E., Aminian, A., Angrisani, L., Cohen, R. V., de Luca, M., Faria, S. L., Goodpaster, K. P. S., Haddad, A., Himpens, J. M., Kow, L., Kurian, M., Loi, K., Mahawar, K., Nimeri, A., O’Kane, M., Papasavas, P. K., Ponce, J., … & Torres, A. (2022). 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) indications for metabolic and bariatric surgery. Surgery for Obesity and Related Diseases, 18(12), 1345–1356.
• Estruch, R., Ros, E., Salas-Salvadó, J., Covas, M. I., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., Fiol, M., Lapetra, J., Lamuela-Raventós, R. M., Serra-Majem, L., Pintó, X., Basora, J., Muñoz, M. A., Sorlí, J. V., Martínez, J. A., & Martínez-González, M. A. (2018). Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. New England Journal of Medicine, 378(25), e34.
• Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503–515.
• Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dusharm, T. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. The Lancet, 376(9741), 595-605.
• Hotamisligil, G. S. (2017). Foundations of immunometabolism and implications for metabolic health and disease. Immunity, 47(3), 406–420.
• Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216.
• Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Zhang, S., Geleske, T., Coskun, T., Haupt, A., & Milicevic, Z. (2023). Triple-hormone-receptor agonist retatrutide for obesity — A phase 2 trial. New England Journal of Medicine, 389(6), 514-526.
• Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., Loria, C. M., Millen, B. E., Nonas, C. A., Pi-Sunyer, F. X., Stevens, J., Stevens, V. J., Wadden, T. A., Wolfe, B. M., & Yanovski, S. Z. (2014). 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Circulation, 129(25 Suppl 2), S102–S138.
• Kessler, R. M., Hutson, P. H., Herman, B. K., & Potenza, M. N. (2016). The neurobiological basis of binge-eating disorder. Biological Psychiatry, 79(8), 639–646.
• McElroy, S. L., Hudson, J. I., Ferreira-Cornwell, M. C., Radewonuk, J., Gasior, M., & Herman, B. K. (2016). Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: Results of two pivotal phase 3 randomized controlled trials. American Journal of Psychiatry, 173(9), 900-910.
• O’Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S.,… & Knop, F. K. (2023). Efficacy and safety of oral semaglutide 50 mg once daily in adults with overweight or obesity (OASIS 1): A randomized, double-blind, placebo-controlled, phase 3 trial. The Lancet, 402(10403), 705-719.
• Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Ortiz, R. V., Jensen, C. B., & Wilding, J. P. H. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11–22.
• Puhl, R. M., & Heuer, C. A. (2010). Obesity stigma: Important considerations for public health. American Journal of Public Health, 100(6), 1019–1028.
• Torgerson, J. S., & Hauptman, J. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Obesity Research, 12(Suppl.), A34.
• Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. Nature, 444(7122), 1027–1031.
• Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002.

SEO Tags: obesity pharmacology, anti-obesity medications, GLP-1 receptor agonists, semaglutide Wegovy, tirzepatide Zepbound, liraglutide Saxenda, obesity treatment El Paso Texas, integrative chiropractic obesity care, functional medicine weight loss, Dr. Alex Jimenez DC, Dr. Maria Guadalupe Cardenas MD, obesity chronic disease, weight bias in healthcare, binge eating disorder treatment, naltrexone bupropion Contrave, phentermine topiramate Qsymia, obesity BMI pharmacotherapy, multidisciplinary obesity management, neuroendocrine appetite regulation, bariatric medicine, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, obesity and musculoskeletal pain, evidence-based weight management, POMC pathway obesity, GIP GLP-1 dual agonist, obesogenic medications, social determinants of obesity, leptin resistance, gut microbiome obesity, rehabilitation, autonomic regulation, diaphragmatic breathing